(+)-Morphine Activates Toll-like Receptor 4 (TLR4) in Endothelial Cells by Reddy, Anireddy
University of Colorado, Boulder
CU Scholar
Undergraduate Honors Theses Honors Program
Spring 2011
(+)-Morphine Activates Toll-like Receptor 4
(TLR4) in Endothelial Cells
Anireddy Reddy
University of Colorado at Boulder
Follow this and additional works at: http://scholar.colorado.edu/honr_theses
This Thesis is brought to you for free and open access by Honors Program at CU Scholar. It has been accepted for inclusion in Undergraduate Honors
Theses by an authorized administrator of CU Scholar. For more information, please contact cuscholaradmin@colorado.edu.
Recommended Citation
Reddy, Anireddy, "(+)-Morphine Activates Toll-like Receptor 4 (TLR4) in Endothelial Cells" (2011). Undergraduate Honors Theses.
Paper 11.
  
 
 
 (+)-Morphine Activates Toll-like Receptor 4 (TLR4) in 
Endothelial Cells 
 
 
 
Anireddy Reddy 
March 30, 2011 
Molecular, Cellular & Developmental Biology 
University of Colorado at Boulder 
 
 
Thesis Advisors 
Dr. Linda Watkins (Department of Psychology and Center for Neuroscience) 
Dr. Lisa Loram (Department of Psychology and Center for Neuroscience) 
 
 
 
Committee Members 
Dr. Robert Poyton (Honors Representative; Molecular, Cellular & Developmental Biology) 
Dr. Mark Winey (Department of Molecular, Cellular & Developmental Biology) 
Dr. Ryan Bachtell (Department of Psychology and Center for Neuroscience) 
 
 
 
 
 
 
 
 
 
2 
ABSTRACT 
Endothelial cells are especially important within the central nervous system as they line 
capillaries and form the blood-brain barrier.  Moreover, they are the first cell type within the 
CNS to be exposed to foreign pathogens and drugs in the bloodstream. In other cell types in the 
CNS, activation of Toll-like Receptor 4 (TLR4) results in activation of transcription factors such 
as NF-κB and AP-1, both known to induce the production of pro-inflammatory cytokines. The 
expression of pro-inflammatory cytokines sensitizes neurons, thus decreasing pain thresholds 
and prolonging pain.  Interestingly, recent research demonstrates that opioids (analgesics 
prescribed for chronic pain) not only bind the µ-opioid receptor to confer pain relief, but also 
activate TLR4.  It is thought that TLR4 activation, and subsequent release of pro-inflammatory 
cytokines, contributes to the negative effects of tolerance, dependence, and withdrawal 
associated with morphine use.  Because of the dearth of research surrounding opioids and their 
effect on this cell type, this study attempted to characterize TLR4 activation in endothelial cells.  
Endothelial cells were isolated from the brain and spinal cord and incubated with various doses 
of (+)-morphine. Results indicate that TLR4 is indeed activated by (+)-morphine, producing 
PGE2 and increasing the mRNA of IκB, CD14, and TLR4 at 100 µM (+) morphine 24 h after 
incubation. The pro-inflammatory response induced by 100 µM (+)-morphine can be blocked 
with both PI3K and IκB-α inhibitors, significantly reducing NF-κB activation and PGE2 
production.  Furthermore, signal transduction occurs in a MyD88-dependent fashion as CLI-095, 
a TLR4 signaling inhibitor that blocks the MyD88-independent pathway, had no significant 
effect on mRNA expression or PGE2 production.  These data suggest that (+)-morphine induces 
TLR4 activation in endothelial cells and, in concert with other cell types in the central nervous 
system, may contribute to the negative effects of morphine use.  
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INTRODUCTION 
Pain management remains a significant health concern, especially for those who suffer 
from chronic pain.  Chronic pain, or pain that persists beyond the natural course of healing, 
affects over five million people in the United States  (Tawfik et al., 2007) and costs over $100 
billion annually in medical expenses and lost productivity (Department of Health and Human 
Services, 1998; Stewart et al., 2003).  Despite advances in pharmacotherapeutics, nearly two-
thirds of chronic pain patients receive little to no relief from current treatments (Sindrup and 
Jensen, 1999; Collins et al., 2000; McQuay et al., 1996).  The most effective class of analgesics 
today is opioids, primarily morphine. Unfortunately, opioids are associated with negative side 
effects such as dependence, tolerance, and subsequent abuse (Compton and Volkow, 2006; 
Manchikanti, 2006).  
Much research has focused on the mechanisms underlying opioid tolerance and 
dependence, and how preventing these side effects can be used to optimize the analgesic effects 
of morphine. One realm of study investigates cells involved in innate immunity, particularly 
endothelial cells. Endothelial cells, which line capillaries, are important in facilitating transport. 
The endothelium is especially important around the central nervous system as it comprises the 
blood-brain barrier (Galley and Webster, 2004) and therefore is the first cell type within the CNS 
to be exposed to foreign pathogens.  Endothelial cells are in contact with and respond to 
substances within the blood, and can be activated in an immune-like response against a harmful 
foreign pathogen (Galley and Webster, 2004).  In the last decade, research has found that 
endothelial cells express Toll-like Receptor 4 (TLR4), a transmembrane protein that recognizes 
foreign pathogens (Gangloff et al. 2003).  In other cell types in the central nervous system, 
activation of TLR4 results in activation of transcription factors such as NF-κB and AP-1, both 
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known to induce the production of pro-inflammatory cytokines (Malcangio et al., 1996; Mika, 
2008; Obreja et al., 2002). The expression of pro-inflammatory cytokines sensitizes neurons, 
thus decreasing the pain threshold and prolonging pain (Malcangio et al., 1996; Mika, 2008; 
Obreja et al., 2002).  While it is known that TLR4 recognizes bacteria, viruses, and fungi 
(Hameed et al., 2010), recent research of TLR4 in microglia, the immunocompetent cells within 
the central nervous system, shows that this receptor also binds morphine (Hutchinson et al., 
2007; Watkins et al., 2009).  Interestingly, in addition to binding opioid receptors to confer pain-
reducing effects, morphine also activates microglia.  This activation has been identified to occur 
in acute and chronic morphine and other opioid administration both within the spinal cord and 
within the brain (Song and Zhao, 2001; Hutchinson et al., 2007).  The microglial activation and 
subsequent pro-inflammatory cytokine release sensitize neurons and diminish the analgesic 
effects of morphine, a mechanism that is thought to be a key contributor to the negative effects of 
opioids (Hutchinson et al., 2007; Watkins et al., 2009).  
During the past decade, studies documenting TLR4 expression in endothelial cells 
indicate that they too may play a role in pro-inflammatory cytokine expression (Jou et al., 2006; 
Tang et al., 2007).  While it is known that TLR4 receptors on endothelial cells respond to some 
TLR4 ligands, such as lipopolysaccharide (Laflamme and Rivest, 2001), there is less research 
surrounding TLR4 activation and morphine in this cell type.  Given the relatively recent 
understanding of TLR4 and its connection to endothelial cells, there is great potential for 
clinically relevant findings. As such, this study will characterize TLR4 activation in response to 
morphine in endothelial cells as well as explore the effects of TLR4 inhibitors on this activation.  
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BACKGROUND 
Given the important functions of the nervous system, the immune system has many 
specialized cells to protect the brain, nerves, and cerebrospinal fluid. Among these cell types are 
endothelial cells, which are part of the innate (non-specific) immune system. Endothelial cells 
are in contact with and respond to substances within the blood, and can be activated in an 
immune response against a harmful foreign pathogen (Galley and Webster, 2004). Endothelial 
cells create capillaries and are necessary in facilitating transport; the endothelium is especially 
important around the central nervous system as it comprises the blood-brain barrier (Galley and 
Webster, 2004). Similar to microglia and astrocytes, endothelial cells also express TLR4 (Faure 
et al., 1999, Jou et al. 2006; Tang et al. 2007), which can recognize potentially harmful 
substances and activate an immune-like response (Tanga, Nutile-McMenemy, & DeLeo, 2005; 
Wang et al., 2010).  This immune response includes the secretion of pro-inflammatory cytokines, 
which recruit neutrophils to the site of injury and mediate the healing process (Martin and Roy, 
2010).    
Toll-like Receptor 4 
 The Toll-like receptor 4 (TLR4) is a transmembrane protein and part of pathogen-
associated molecular pattern receptors that identify and mount a response to exogenous threats.  
In other words, these TLRs recognize patterns indicative of bacteria, fungi, and viruses that are 
potentially harmful and trigger an inflammatory signaling cascade to attract other 
immunocompetent cells to combat the foreign substance (Hameed et al., 2010).  TLR4, in 
particular, responds to components of the cell wall of gram-negative bacteria (Gangloff et al., 
2003) such as lipopolysaccharide (LPS) (Shimazu et al., 1999; Poltorak et al., 1998; Lehnardt et 
al., 2003; Hoshino et al., 1999).  Additionally, TLR4 is important for recognizing endogenous 
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danger signals from injured or dying cells, including heat shock proteins, plasma proteins, and 
extracellular matrix degradation products (Tanga et. al., 2005; Kim et al., 2007).  
While binding of LPS and related ligands triggers TLR4 signaling, signal transduction is 
also dependent upon recruitment of other extracellular proteins (Fig. 1).  For example, the 
myeloid differentiation factor 2 (MD-2) is required to bind to TLR4 (Shimazu et al., 1999; Nagai 
et al., 2002) and this TLR4/MD-2 complex must join another complex to form a homodimer in 
the plasma membrane (Kobayashi et al., 2006; Prohinar et al., 2007; Laird et al., 2009).  In most 
cell types, this homodimer must additionally bind to the GPI-anchored protein CD14 for signal 
transduction to occur (Wrigtht et al., 1990; Haziot et al., 1988). However, in endothelial cells 
CD14 is not on the plasma membrane of the cell; rather, endothelial TLR4s interact with the 
soluble CD14 that flows in the bloodstream (Frey et al., 1992; Arditi et al., 1993; Haziot et al., 
1993; Pugin et al., 1993; Galley and Webster, 2004). Then the resulting complex confers an 
intracellular signal via the Toll/IL-1 receptor (TIR) domain (Gangloff et al., 2003; Kim et al., 
2007; Rittirsch et al., 2009) that either follows a MyD88-dependent or MyD88-independent 
pathway.  MyD88 is a protein in the cytoplasm that similarly possesses a TIR domain, which 
interacts with the TIR domain of TLR4 (Horng et al. 2002; Laird et al., 2009).  In the MyD88-
dependent pathway, the resulting signal is then transduced to IL-1 receptor-associated kinases 
(IRAKs) that facilitate subsequent phosphorylations in the signaling cascade (Kawai et al., 1999; 
Kawai and Akira, 2007; Dauphine and Karsan, 2006).  These phosphorylations ultimately 
activate the transcription factors NF-κB and AP-1, which trigger an innate immune response in 
the central nervous system (Laflamme and Rivest, 2001) and promote expression of pro-
inflammatory cytokines such as IL-1β and IL-6 (Watkins and Maier, 2000; DeLeo et al., 2000; 
Tanga et al., 2005; Hutchinson et al., 2007). NF-κB is comprised of two subunits, p65 and p50 
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and is inhibited by IκB-α (Greene et al., 1993). IκB-α is a cytoplasmic protein that binds the 
nuclear localization sequence of the p65 subunit such that NF-κB is not translocated to the 
nucleus (Greene et al., 1993).  Upon phosphorylation, triggered by activated IRAKs, IκB-α 
dissociates from NF-κB and allows NF-κB to enter the nucleus and modulate transcription.  For 
this study transcripts and proteins involved in the TLR4 signaling cascade, primarily TLR4, MD-
2, CD14, IκB, NF-κB, and IL-1β, were measured to determine TLR4 activation.  
  
Fig. 1. Signaling pathway of Toll-like Receptor 4 (TLR4) 
TLR4 signal transduction requires recruitment of myeloid differentiation factor 2 (MD-2) and soluble 
CD14 that flows in the bloodstream.  The resulting complex confers an intracellular signal via the 
Toll/IL-1 receptor (TIR) domain that either follows a MyD88-dependent or MyD88-independent 
pathway. In the MyD88-dependent pathway, the resulting signal is then transduced to IL-1 receptor-
associated kinases (IRAKs) that facilitate subsequent phosphorylations.  These phosphorylations 
ultimately cause IκB-α, a cytoplasmic protein that binds the nuclear localization sequence of the p65 
subunit of NF-κB, to dissociate from NF-κB. Binding of TLR4 also activates the PI3K/Akt/NF-κB 
pathway.  NF-κB then translocates to the nucleus to promote transcription of pro-inflammatory 
cytokines such as IL-1β and IL-6. TLR2 activity requires CD14 and contributes to NF-κB activation.  
TLR4 signaling also involves MAP kinase activity, which promotes COX2 transcription and ultimately 
the production of PGE2. (Gangloff et al., 2003; Shimazu et al., 1999; Zhang, 2011) 
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Another Toll-like receptor, TLR2, contributes to pro-inflammatory cytokine expression 
and is implicated in chronic morphine use (Zhang, 2011).  While TLR4 was traditionally thought 
to bind exclusively to Gram-negative bacteria and TLR2 was thought to bind Gram-positive 
bacteria, research shows that both receptors bind many other ligands and often bind the same 
ligand with differing affinities (Dziarski et al., 2001; Muta and Takeshige, 2001).  For example, 
both receptors can bind LPS, but TLR4 has a binding affinity that is approximately 100 times 
greater than TLR2 (Muta and Takeshige, 2001).  Similar to TLR4, TLR2 recruits CD14 and can 
trigger the MyD88-dependent signaling pathway that ultimately increases expression of NF-κB, 
though it is unclear whether MD-2 is required (Dziarski et al., 2000; Dziarski et al., 2001; 
Yoshimura et al., 1999; Muta and Takeshige, 2001).  Interestingly, in addition to promoting the 
anti-apoptotic PI3K/Akt/ NF-κB pathway, TLR2 signaling also promotes apoptosis via factors 
such as FADD/p53 (Yin et al., 1999; Yin et al., 2006).  It is thought that the apoptosis resulting 
from TLR2 activation may be the mechanism behind the decreased strength of the immune 
system and increased susceptibility to disease in chronic morphine use (Yin et al., 1999; Yin et 
al., 2006; Li et al., 2010).  Moreover, inhibiting TLR2 expression in chronic morphine models 
decreased cell death (Li et al., 2010).  With regards to TLR2 and pro-inflammatory cytokine 
expression, it has been shown that TLR2 is required for morphine-induced microglia activation, 
which results in increased inflammatory response (Zhang et al., 2011).  This glial activation has 
already been implicated in morphine tolerance, dependence, and withdrawal (Peterson et al., 
1998) therefore demonstrating the important role of TLR2 in morphine use.  Given the 
similarities between TLR2 and TLR4 signaling pathways, TLR2 expression was also measured 
in this study.  
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The role of TLR4 in pain 
The immune system was first implicated in morphine tolerance and dependence when it 
was observed that immunosuppressive treatments could alleviate withdrawal symptoms (Dafny 
et al.,1990).  However, only recently has TLR4 activity on immunocompetent cells been 
connected to neuropathic pain (Malcangio et al., 1996; Mika, 2008; Obreja et al., 2002; 
Hutchinson et al., 2008). One of the clues linking TLR4 and pain was research showing that 
intrathecal administration of IL-1β induced allodynia and hyperalgesia (Malcangio et al., 1996; 
Mika, 2008; Obreja et al., 2002). Since IL-1β is a product of TLR4 signaling, studies further 
explored the role of TLR4 in neuropathic pain.  One study demonstrated that TLR4 knockout 
mice showed decreased pro-inflammatory cytokine release and hypersensitivity (Tanga et al., 
2005).  The same researchers also found that TLR4 knockout mice and rats with intrathecal 
injections of TLR4 antisense oligodeoxynucleotide (to decrease spinal expression of TLR4) 
showed reduced allodynia and pro-inflammatory cytokine release after L5 nerve transection 
(Tanga et al., 2005).  Following in this trend were results of experiments involving sciatic nerve 
chronic constriction injury (CCI), a rat model of partial nerve damage known to cause chronic 
pain in people and induce allodynia (where normally non-painful stimuli become painful) in rats.  
Rats experienced allodynia and pro-inflammatory cytokine release following the CCI surgery, 
both of which could be reversed via acute blockade of TLR4 (Hutchinson et al., 2007).  Taken 
together, these studies illustrated the important function of TLR4 signaling in neuropathic pain, 
but they have focused primarily on glial cells.  Since endothelial cells also express TLR4, it is 
important to assess their role in releasing sensitizing factors that promote neuropathic pain and 
decrease the analgesic effects of opioid treatment.  
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Morphine and TLR4 
The traditional understanding of opioid-receptor interactions asserts that opioids interact 
primarily with opioid receptors.  Morphine, for instance, binds to the µ-opioid receptor on 
neurons to inhibit voltage-gated calcium channels, thus decreasing excitatory neurotransmission 
and promoting analgesia (Martin and Roy, 2010; Griffin, 2008).  More specifically, the µ-opioid 
receptor only interacts with the (-)-opioid stereoisomer in order to achieve analgesic effects; in 
fact, administration of the (+)-opioids has little to no analgesic effect (Wu et al., 2006).     
Interestingly, it was not until research of the opioid receptor antagonist naloxone (used to 
treat opioid overdose) was conducted that alternative opioid-receptor interactions were 
conceived.  A study examining the effects of naloxone on LPS-induced glial activation showed 
that pro-inflammatory cytokine release could be comparably mitigated by (-)-naloxone as well as 
(+)-naloxone (Liu et al., 2000).  Because the µ-opioid receptor only binds the (-)-isomer, these 
findings indicated that naloxone was binding a different receptor, which could bind both isomers 
and reverse LPS-induced activation.  Subsequent research traced LPS-induced signaling and 
identified TLR4 as the other receptor that interacts with both (+) and (-)-opioid isomers (Wu et 
al., 2006; Hutchinson et al., 2008).   
Once opioids were identified as TLR4 ligands, studies focused on how these interactions 
could be contributing to the molecular and physiological effects of opioid treatments.  The 
hypothesis was that non-stereoselective binding of morphine to TLR4 activates the signaling 
cascade that results in pro-inflammatory cytokine expression, and this expression ultimately 
diminishes the analgesic effects of morphine (Milligan and Watkins, 2005; Watkins, Rice, and 
Maier, 2009).  To explore this hypothesis, researchers studied the effects of (+)-naloxone on 
LPS-induced inflammation; as expected, naloxone acted as a noncompetitive antagonist of TLR4 
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and decreased the LPS-induced inflammatory effects (Liu et al., 2000; Hutchinson et al., 2009b).  
As mentioned earlier, TLR4 is already a significant player in CCI-induced allodynia, a state that 
could be reversed upon (+)-naloxone administration (Hutchinson et al., 2007).  Additionally, 
potentiation of analgesia was observed when morphine and (+)-naloxone were co-administered 
as well as in related studies with morphine administration in TLR4 knockout mice (Buchanan et 
al., 2010; Hutchinson et al., 2009b).  Overall, these studies indicate that (+)-opioid receptor 
antagonists have therapeutic potential because they can selectively reduce the inflammatory 
effects of the TLR4 pathway without interfering with the interactions at the opioid receptors 
(Hutchinson et al., 2007).  Given the stereoselectivity of the µ-opioid receptor, (+)-morphine was 
used in this study so that TLR4 could exclusively be examined, absent of the confounding effects 
of (-)-morphine binding at the µ-opioid receptor.   
 Given that morphine-TLR4 interactions trigger pro-inflammatory cytokine release, which 
counteracts the analgesic effects of morphine, it is reasonable to infer that the TLR4 mechanism 
may be involved with morphine tolerance.  Tolerance, or the need for larger doses to achieve the 
same effect, is one of the primary reasons physicians are reluctant to prescribe opioids for 
chronic treatments.  Not only are larger doses of drug needed over time to alleviate pain, but also 
the higher doses can lead to serious addiction and abuse problems (Martin and Roy, 2010).  
Many studies show that chronic morphine increases glial activation and subsequent pro-
inflammatory cytokine release; moreover, glial activation inhibitors restore the analgesic 
efficacy, therefore preventing the need to administer higher doses of morphine to achieve the 
same analgesic effects (Song and Zhao, 2001; Raghavendra et al., 2003; Mika et al., 2007).  This 
glial activation can occur through trauma, injury, etc. or, in the case involving TLR4, exposure to 
LPS (Wu et al., 2006; Johnston and Westbrook, 2005).  In other words, the antinociceptive 
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effects of morphine combined with the pronociceptive effects of glial activation result in net 
decrease in analgesic effect (Hutchinson et al., 2007).  This transient reduction of analgesic 
effect produces acute tolerance that can, quite quickly, develop into serious analgesic tolerance 
as well as contribute to the allodynia and hyperalgesia associated with chronic morphine use 
(Hutchinson et al., 2007).  The mitigation of analgesic effects via glial activation may also play a 
role in dependence and reward pathways, which makes TLR4 signaling and inflammation an 
even more compelling therapeutic target.  Studies illustrate that administration of a glial 
activation inhibitor with morphine can reduce conditioned place preference, indicating that the 
rewarding aspects of morphine decrease and similarly reduces development of the associated 
dependency behaviors (Narita et al., 2006; Nakagawa and Satoh, 2004; Ozawa et al., 2001).  
Once again, current studies provide intriguing evidence for the role of glial TLR4 in pain and 
opioid tolerance and dependence; however, research is lacking surrounding TLR4 activation in 
endothelial cells and how it may also contribute to negative effects of chronic opioid use.  
Moreover, because endothelial cells are the first cell type of the central nervous system to 
encounter intravenous opioids, it is important to characterize how these cells may respond.   
MATERIALS & METHODS 
Endothelial Cell Isolation & Culture 
Endothelial cells were isolated from adult male Sprague-Dawley rats (300-375g, Harlan 
Laboratories, Madison, WI, USA).  Rats were deeply anesthetized with isoflurane and then 
rapidly decapitated. The brain and spinal cord were dissected out and the meninges removed. 
The brain and spinal cord tissue was placed in 50 mL of ice-cold DMEM solution (Invitrogen, 
Carlsbad, CA, USA) supplemented with 100 µg/mL Penicillin-Streptomyocin solution 
(Invitrogen), 50 µg/mL Gentamicin (Invitrogen), and 2 mM GlutaMAX-1 (Invitrogen).  Under a 
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cell culture hood, the supplemented DMEM was removed and the tissue placed in a petri dish 
with 13.5 mL HBSS containing 200U/mL Collagenase II (Invitrogen) and 30U/mL DNase I 
(Sigma, St Louis, MO, USA).  Using a sterile scalpel, the tissue was finely minced into small 
pieces and transferred to a 50 mL conical and incubated for 40 min at 37 ˚C.  10 mL of HBSS 
was added and the cell suspension centrifuged at 1000 x g for 8 min at 4˚C.   The supernatant 
was removed and the pellet resuspended in 30 mL of 20% BSA in DMEM and centrifuged at 
1000 x g for 20 min at 4˚C. The myelin layer lying at the surface was removed and 10 mL of 
HBSS containing 10 mg collagenase/dispase (Roche), and 300U DNase I stock (Sigma) was 
added to the pellet and incubated at 37˚C for 30 min.  10 mL of HBSS (Ca2+ and Mg2+ free) was 
added and centrifuged at 700 x g for 6 min at 4˚C.  The supernatant was removed and the pellet 
resuspended in 2 mL of supplemented DMEM and gently layered over a 37% Percoll gradient 
containing 3.3% FBS. The Percoll gradients were centrifuged at 1000 x g for 10 min at 4˚C (no 
brake or acceleration).  At the interface of the gradient, the white layer containing the desired 
microvessel fragments was collected using a 1.5 inch 18G needle and added to 25 mL of cold 
supplemented DMEM.  The solution was centrifuged at 1000 x g for 10 min at 4˚C.  The 
supernatant was removed and the remaining pellet resuspended in 48 mL warm DMEM 
(Invitrogen), containing 100 µg/mL Penicillin-Streptomyocin solution, 50 µg/mL Gentamicin, 2 
mM GlutaMAX-1, 20% FBS, 1 ng/mL basic fibroblast growth factor (bFGF), and 1 µg/mL 
puromycin. The cells were seeded into 24 well tissue culture plates previously coated with 8 µg 
fibronectin, 16 µg collagen type IV, and 8 µg collagen type I. Cells were incubated for 48 hours 
at 37 °C and 5% CO2.   
 After the first 48-hour incubation period, the medium was removed and each well was 
washed twice with PBS (to remove the puromycin).  Then, 1 mL of warm culture medium 
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without puromycin was added to each well.  Every 2-3 days the medium was replaced until the 
cells were 60-80% confluent (about 7-8 days). 
RNA extraction, cDNA synthesis, and Reverse-Transcription PCR 
The RNA was extracted from the cells using TriZol (Invitrogen). 160 µL of chloroform 
was added to each sample.  After 2 minutes of vortexing and 3 minutes of incubation at room 
temperature, the samples were centrifuged at 11900 x g for 15 minutes at 4˚C.  The aqueous 
phase was collected and 8 µL of glycogen was added to each sample and vortexed.  Then, 400 
µL of propanol was added to each sample, vortexed, and incubated at room temperature for 10 
minutes.  The samples were centrifuged at 11900 x g for 10 minutes at 4˚C.  Following this step, 
a pellet was visible and the supernatant was poured out and replaced with 1 mL of 75% ethanol 
(75% ethanol and 25% nuclease-free water).  The samples were centrifuged at 7500 x g for 10 
minutes at 4˚C and the previous step was repeated (removing supernatant and replacing with 
75% ethanol).  After centrifuging again at 7500 x g for 10 minutes at 4˚C, the samples dried for 
about 30 minutes.  The pellets were then resuspended in 11 µL nuclease-free water (on ice) and 
transferred to thermal well 0.5 mL tubes. 
 Following RNA extraction the Superscript II First-Strand Synthesis System (Invitrogen) 
was used to reverse transcribe RNA into cDNA. For cDNA synthesis, 5 ng/µL of random primer 
and 1 mM dNTP mix (Invitrogen) was added to each sample and incubated for 5 minutes at 
65˚C.  The samples were immediately transferred to ice and a 6 µL mixture of 5X buffer 
(Invitrogen) and 10 mM dithiothreitol was added to each sample; the samples were incubated for 
2 minutes at 25˚C.  Then, 200U of SuperScript II (Invitrogen) was added to each sample and 
incubated for 10 minutes at 25˚C, 50 minutes at 42˚C, and 15 minutes at 25˚C.  The samples 
were then stored at -20˚C until further use.  
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 The quantification of mRNA involves amplifying cDNA using Real-Time PCR 
machines.  A 26 µL mixture of Quantitect SYBR Green PCR Master Mix (Qiagen, Valencia, 
CA, USA), 10 nM fluorescein, 500 nM forward and reverse primers (Invitrogen), and nuclease-
free water, and 1 µL of sample cDNA was added to each well in a 96-well PCR plate (Bio-Rad, 
Hercules, CA).  To minimize error, cDNA was added in duplicate and the resulting average was 
used for statistical analysis.  Primers for the following genes were used: GAPDH, TLR4, CD14, 
MD-2, TLR2, IκB, and IL-1β.  After 40 cycles  (of 15 seconds at 94˚C, 30 seconds at 55–60˚C, 
and 30 seconds at 72˚C) on the MyiQ Real-Time PCR machine (Bio-Rad), the threshold cycle 
data (CT-number of cycles for sample to amplify) was collected. 
In-Cell Western Assay 
The In-Cell Western assay was used to measure cellular protein expression in the 
endothelial cells.  The supernatants were removed immediately after the corresponding drug 
incubation time and the cells fixed in 1 mL/well of 4% paraformaldehyde for 20 minutes at room 
temperature. The paraformaldehyde was removed and the cells were permeabilized with 1 
mL/well of 1X PBS with 0.1% Triton X-100 (Li-Cor, Lincoln, NE, USA) for five minutes, at 
room temperature on a gentle rocker.  The cells were washed 5 times with 1X PBS with 0.1% 
Triton X-100. 1 mL of Odyssey Blocking Buffer (Li-Cor) was added to each well to block non-
specific binding sites and incubated on a rocker for 90 min at room temperature.  After 
incubation, 1 mL of the primary antibody (diluted in Odyssey Blocking Buffer) was added to all 
wells except the control well (1 mL of Odyssey Blocking Buffer only).  The antibodies used in 
this study were MD-2 (1:200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD14 
(1:100 dilution, Abcam, San Francisco, CA, USA), and the p65 subunit of NF-κB (1:500 
dilution, Millipore, Billerica, MA, USA).  Cells were incubated at 4˚C overnight with gentle 
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rocking.  The cells were then washed five times with 1 mL of 1X PBS + 0.1% Tween-20. 500 µL 
of secondary antibody only (1:800 dilution in Odyssey Blocking Buffer) was added to the control 
well and protected from the light.  Then a 1:2000 dilution of DRAQ5 (Li-Cor) was added to the 
secondary antibody solution and 500 µL of this solution was added to all remaining wells.  
DRAQ5 is a fluorescent stain in the 700 nm channel that binds DNA in live or fixed cells; this 
stain is used to normalize the antibody signal (in the 800 nm channel) to the number of cells in 
each well. The cells were incubated for one hour at room temperature, protected from the light, 
with gentle rocking. The secondary antibody solution was removed and each well was washed 
five times with 1 mL of 1X PBS + 0.1% Tween-20 Solution (Li-Cor).  Following the final wash, 
each plate was tapped to dry.  The dry plates were scanned by the Odyssey Infrared Imaging 
System in the 700 nm (DRAQ5) and 800 nm (antibody) channels. Using the measurements of the 
control well to define background, non-specific antibody binding, the integrated intensity for the 
700 nm and 800 nm channels was calculated.   
PGE2 Competitive Immunoassay 
Prostaglandin E2 (PGE2), which is produced by cyclooxygenase 2 (COX2), is also a 
product of TLR4 signaling.  Unlike IL-1β, PGE2 is synthesized independently of NF-κB, though 
is does rely on PI3K (Hernandez et al., 2010; Rodríguez-Barbero et al., 2009).  Since PGE2 
expression increases with TLR4 signaling, measuring PGE2 is another way in which TLR4 
activation can be quantified.  The concentration of PGE2 in supernatants was determined by 
using a PGE2 competitive immunoassay kit (Cayman Chemical Company, Ann Arbor, MI, USA) 
according to manufacturer’s protocol.  
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Drug Administration  
Experiment I: (+)-morphine timecourse 
In order to ascertain the effect of (+)-morphine at different time points and doses, the 
cells were incubated with 100 µM, 10 µM, 1 µM, and 0 µM doses of (+)-morphine (supplied by 
Dr. Kenner Rice, National Institute on Drug Abuse, Bethesda, MD, USA) for either 2, 4, or 24 
hours.  (+)-morphine was used so that the effect of opioid activity on TLR4 could exclusively be 
examined in the absence of the confounding effects of µ-opioid receptor binding.  A limulus 
amebocyte lysate (LAL) test, which measures the presence of endotoxins, determined that there 
were no detectable levels of endotoxin in (+)-morphine. The morphine was dissolved in sterile 
water and stored at 4˚C.   
Experiment II: Blockade of TLR4 signaling 
In order to identify the intracellular pathways involved following TLR4 activation by (+)-
morphine, the TLR4 pathway was blocked at known key mediators. The three inhibitors, CLI-
095 (Invivogen), Wortmannin (Invivogen), and Bay11-7082 (Invivogen), were dissolved in 
100% DMSO and stored at -20˚C.  CLI-095 prevents TLR4 signaling by blocking the 
dimerization of receptors at the plasma membrane in a MyD88-independent fashion. Cells were 
incubated with CLI -095 two hours prior to administration of 100 µM (+)-morphine. 
Wortmannin inhibits PI3K, which is needed to activate the transcription factor NF-κB; cells were 
incubated with Wortmannin for one-hour before administration of 100 µM (+)-morphine. 
Another set of cells were incubated for 30 minutes before 100 µM (+)-morphine with Bay11-
7082, which prevents phosphorylation of IκB-α such that NF-κB cannot be localized to the 
nucleus. Each drug was administered at 10 µM, 1 µM, 0.1 µM, and 0 µM doses in the presence 
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and absence of (+)-morphine.  Twenty-four hours after (+)-morphine administration, 
supernatants were collected and cells processed for RT-PCR.  
Statistical analysis 
PCR data was normalized by converting CT values to percent of GAPDH (housekeeping 
gene) and by excluding the maximum (ΔCT) value.  Within each dose and time group for all 
results, outliers that were three standard deviations from the mean were excluded from statistical 
analysis.  To compare doses at different times, all mRNA and protein results were converted to 
percent of vehicle measures.  All data were analyzed using one-way analysis of variance 
(ANOVA) comparing variance across drug dose. For experiment I each time interval was 
analyzed separately. 
RESULTS 
Upregulation of IκB and IL-1β mRNA with (+)-morphine administration 
IL-1β is one of the final outputs of the TLR4 pathway and is one of many pro-
inflammatory cytokines that contributes to morphine tolerance and dependence.  Increased IL-1β 
mRNA would demonstrate that (+)-morphine administration triggers increased transcription of 
this pro-inflammatory cytokine. IL-1β mRNA (Fig. 2A) increased significantly (F3,17= 6.42, P < 
0.05) at 2 h with the 100 µM dose when compared to vehicle and decreased over time.  
IκB is an inhibitory kinase that, when phosphorylated, is cleaved from the transcription 
factor NF-κB.  This cleaving process exposes the nuclear localization signal on NF-κB, allowing 
NF-κB to translocate to the nucleus and promote transcription of pro-inflammatory cytokines.  
An increase in IκB mRNA provides an indirect measure of increased NF-κB activity. IκB 
mRNA (Fig. 2B) was significantly greater (F3,20= 120.17, P < 0.001) than vehicle at the 100 µM 
(+)-morphine dose at 2 h and 24 h, but not at 4 h (F3,20= 120.17, P > 0.05).     
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Upregulation of Toll-like receptor mRNA with (+)-morphine administration 
If (+)-morphine binds TLR4, it is important to measure whether TLR4 transcription is 
altered in response to (+)-morphine administration.  Due to TLR4 activation, there may be 
increased TLR4 transcription to replace receptors that are ligand-bound and internalized or to 
increase receptors on the plasma membrane.  TLR4 mRNA (Fig. 3A) did not show significant 
increases at 2 h or 4 h (F3,20= 5.50, P >  0.05).  At 24 h, TLR4 mRNA was significantly greater at 
the 100 µM (+)-morphine dose compared to vehicle (F3,20= 5.50, P <  0.05).   
Since it is possible that TLR2 is activated by (+)-morphine, TLR2 transcripts were 
measured as well.  TLR2 mRNA (Fig. 3B) was significantly greater at the 100 µM (+)-morphine 
at 2 h (F3,16= 5.30, P <  0.05) and then significantly less at 4 h (F3,20= 21.59, P < 0.0001). It 
appears that the 100 µM (+)-morphine caused TLR2 mRNA to increase quickly at 2h and 
diminish, while TLR4 mRNA did not significantly increase until later at 24 h post drug 
administration.    
Upregulation of CD14 and MD-2 mRNA with (+)-morphine administration 
Two of the accessory proteins required to form the TLR complex are CD14 and MD-2; 
while both are required for TLR4 signaling, only CD14 is necessary for TLR2.  While CD14 
mRNA (Fig. 4A) was not significantly greater at 2 h and 4 h after drug administration, 100 µM 
(+)-morphine produced a significant increase (F3,20= 5.92, P < 0.05) in CD14 mRNA compared 
to vehicle.  MD-2 mRNA (Fig. 4B) was significantly greater (F3,20= 7.83, P < 0.001) at 100 µM 
(+)-morphine compared to vehicle at 4 h and approached significance at 24 h (F3,20= 7.83, P = 
.080).  The mRNA expression of both CD14 and MD-2 mirrors that of TLR4, which was 
significant at 100 µM (+)-morphine compared to vehicle at 24 hours.  
 
20 
Effects of (+)-morphine administration on protein expression 
While measuring mRNA is important, it is equally vital to measure protein expression, as 
transcription does not always lead to translation.  To ascertain whether changes in mRNA were 
reflected in protein, NF-κB (p65 subunit), CD14, and MD-2 was measured using an In-Cell 
Western assay. While NF-κB expression (Fig. 5A) at the 100 µM dose increased at 24 hours, it 
was not statistically significant.  Of the three proteins analyzed, CD14 (Fig. 5B) was the only 
protein that significantly increased following (+)-morphine administration.  At 24 h both 10 µM 
and 100 µM (+)-morphine significantly increased CD14 protein (F3,18= 11.05, P < 0.01 and P < 
0.001 respectively) compared to vehicle.  However, CD14 protein at the 100 µM (+)-morphine 
dose was significantly downregulated (F3,18= 190.10, P < 0.0001) at 4 h compared to vehicle.  
MD-2 protein levels (Fig. 5C) did not show any demonstrable trend at 2 h and 4 h and showed 
significant decreases at 100 µM and 10 µM (+)-morphine doses (F3,18= 4.294, P < 0.05 and P < 
0.05 respectively),  which is contrary to the mRNA results showing that MD-2 transcripts were 
significantly higher at 4 h.  While mRNA and protein trends matched, in general, for NF-κB and 
CD14, the same was not true for MD-2.  
The effect (+)-morphine on prostaglandin E2 expression 
Another downstream product, which is independent of NF-κB, of TLR4 signaling is 
expression of cyclooxygenase 2 (COX2), producing prostaglandin E2 (PGE2) (Hernandez et al., 
2010).  Moreover, in TLR4 deficient mice (TLR4-/-), PGE2 expression is severely reduced 
(Hernandez et al., 2010).  Consequently, measuring PGE2 is another way in which TLR4 
activation can be quantified. PGE2 was measured at 100 µM, 10 µM, 1 µM, and 0 µM at 24 h 
(Fig. 6). While there was no significant difference at 10 µM and 1 µM doses of (+)-morphine, 
PGE2 expression was significantly higher than vehicle at 100 µM (+)-morphine (F3,38= 4.80, P < 
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0.05).  These results, in combination with mRNA and In-Cell Western assay data, showed 100 
µM (+)-morphine to have the most significant effects.  Thus 100 µM (+)-morphine was used for 
later experiments with TLR4 inhibitors, in order to better assess the effect of these inhibitors on 
the TLR4 pathway.  
The effect of TLR4 signaling inhibitor and (+)-morphine on mRNA 
The administration of a TLR4 signaling inhibitor (CLI-095) was used to determine 
whether disrupting TLR4 dimerization upstream would inhibit transcription of proteins 
downstream in the signaling cascade.  Both IL-1β (Fig. 7A) and IκB mRNA (Fig. 7B) showed 
similar trends of increased expression at 10 µM CLI-095 + 100 µM (+)-morphine, but this 
relationship was not significant with respect to vehicle (F5,13= 4.26 and  F5,14= 1.84 respectively, 
P > 0.05). IL-1β and IκB transcripts for 1 µM CLI-095 + 100 µM (+)-morphine and 0.1 µM 
CLI-095 + 100 µM (+)-morphine were comparable to vehicle.  There was no demonstrable trend 
in TLR4 transcripts (Fig. 7C) at any dose of CLI-095 compared to vehicle.  CD14 (Fig. 7D) 
showed slight downregulation of mRNA at 10 µM CLI-095 + 100 µM (+)-morphine and 1 µM 
CLI-095 + 100 µM (+)-morphine. However, the decrease was not significant (F5,18= 2.70, P > 
0.05).  Similar to IL-1β and IκB, MD-2 mRNA (Fig. 7E) increased at 10 µM CLI-095 + 100 µM 
(+)-morphine; unlike IL-1β and IκB, though, mRNA levels were greater than vehicle at 1 µM 
CLI-095 + 100 µM (+)-morphine and 0.1 µM CLI-095 + 100 µM (+)-morphine.  Once again, 
none of these changes were significant (F5,19= 1.67, P > 0.05).  
The effect of PI3K inhibitor and (+)-morphine on mRNA 
The second TLR4 signaling inhibitor was Wortmannin, a PI3K inhibitor.  PI3K is 
involved in phosphorylating IκB-α, which is needed to expose the nuclear localization sequence 
of NF-κB.  Wortmannin blocks PI3K activity, thus preventing signaling through the 
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PI3K/Akt/NF-κB pathway.  Since PI3K is also involved in other cell survival signaling 
pathways, it is reported to have both anti-inflammatory and pro-inflammatory effects (Laird et 
al., 2009). While all mRNA levels showed a trend of increased transcription at 100 µM (+)-
morphine compared to vehicle, with the exception of CD14, none of these relationships were 
significant. IL-1β transcripts (Fig. 8A) were downregulated at the 1 µM CLI-095 + 100 µM (+)-
morphine and 0.1 µM CLI-095 + 100 µM (+)-morphine; however, at the highest dose 10 µM 
CLI-095 + 100 µM (+)-morphine, IL-1β mRNA increased.  IκB mRNA (Fig. 8B) similarly 
showed upregulation at 10 µM CLI-095 + 100 µM (+)-morphine, while other doses were 
comparable to 100 µM (+)-morphine levels. For both IL-1β and IκB, the changes in mRNA were 
not significant.  Transcripts of TLR4 (Fig. 8C) and MD-2 (Fig. 8E) for all doses of Wortmannin 
+ 100 µM (+)-morphine were comparable to 100 µM (+)-morphine, with no significant 
variations in mRNA.  For CD14 (Fig. 8D), however, mRNA was significantly less at 10 µM 
CLI-095 + 100 µM (+)-morphine (F3,14= 11.48, P < 0.001, P < 0.05), 1 µM CLI-095 + 100 µM 
(+)-morphine (P < 0.01), and 0.1 µM CLI-095 + 100 µM (+)-morphine (P < 0.01) compared to 
100 µM (+)-morphine.  Vehicle and 10 µM CLI-095 mRNA were also significant with respect to 
100 µM (+)-morphine (P < 0.01 and P < 0.0001 respectively).   Overall, while general trends 
showed increased transcription at 100 µM (+)-morphine compared to vehicle, there was no 
significant downregulation of transcripts with Wortmannin except for CD14.  
The effect of IκB-α inhibitor and (+)-morphine on mRNA 
Compared to CLI-095 and Wortmannin, the IκB-α inhibitor Bay11-7082 works much 
further downstream in the TLR4 signaling pathway.  By blocking the phosphorylation of IκB-α, 
Bay11-7082 allows IκB-α to hide the nuclear localization sequence of NF-κB, thus preventing 
NF-κB from translocating to the nucleus.  With the exception of IL-1β, all the other protein 
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transcripts were significantly downregulated at 10 µM drug + 100 µM (+)-morphine compared to 
100 µM (+)-morphine. IL-1β (Fig. 9A) showed increased mRNA at all doses compared to 100 
µM (+)-morphine, though none were significantly greater. IκB mRNA (Fig. 9B), on the other 
hand, was significantly less at 1 µM drug + 100 µM (+)-morphine (F5,13= 17.32, P <  0.05) and 
10 µM drug + 100 µM (+)-morphine (P <  0.001) compared to 100 µM (+)-morphine. Vehicle 
and 10 µM Bay11-7082 mRNA were also significantly less with respect to 100 µM (+)-
morphine (P < 0.001 and P < 0.001 respectively).  TLR4 transcripts (Fig. 9C) were similarly 
downregulated at 1 µM drug + 100 µM (+)-morphine (F5,15= 120.17, P <  0.05) and 10 µM drug 
+ 100 µM (+)-morphine (P < 0.001) compared to 100 µM (+)-morphine.  While CD14 
transcripts (Fig. 9D) were not significantly less at 1 µM drug + 100 µM (+)-morphine, there was 
significant downregulation at the higher dose 10 µM drug + 100 µM (+)-morphine (F5,15= 29.70, 
P <  0.0001) with respect to 100 µM (+)-morphine.  Similar to CD14, MD-2 mRNA (Fig. 9E) 
was only downregulated at 10 µM drug + 100 µM (+)-morphine (F5,14= 8.06, P <  0.05), 10 µM 
Bay11-7082 (P <  0.05), and vehicle (P <  0.05).   The overall trend demonstrated significant 
downregulation of all mRNA (except IL-1β) at 10 µM drug + 100 µM (+)-morphine and at 1 µM 
drug + 100 µM (+)-morphine for TLR4 and IκB.  
The effect of TLR4 inhibitors and (+)-morphine on prostaglandin E2 expression 
In order to determine whether the various TLR4 inhibitors had any effect on PGE2 
synthesis, PGE2 was measured in the supernatant. In response to the TLR4 inhibitor (Fig. 10A) 
there were no significant variations with respect to 100 µM (+)-morphine, although PGE2 levels 
were higher for 100 µM (+)-morphine compared to vehicle and all other doses of CLI-095 were 
comparable to vehicle.  For the PI3K inhibitor (Fig. 10B), on the other hand, PGE2 expression at 
all doses was significantly less compared to 100 µM (+)-morphine; this is consistent with 
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previous research stating that while PGE2 production is independent of NF-κB, it still requires 
PI3K (Rodríguez-Barbero et al., 2006).  PGE2 is significantly less at 10 µM Wortmannin + 100 
µM (+)-morphine (F5,20= 70.12, P < 0.01), 1 µM Wortmannin + 100 µM (+)-morphine (P <  
0.01), 0.1 µM Wortmannin + 100 µM (+)-morphine (P <  0.01), 10 µM Wortmannin (P <  0.05), 
and vehicle (P <  0.01).  PGE2 levels for the IκB-α inhibitor (Fig. 10C) show a dose dependent 
decrease with respect to 100 µM (+)-morphine though, similar to TLR4 inhibitor results, there is 
no significant variation.  Overall, the three TLR4 inhibitors demonstrate a downregulation of 
PGE2 with respect to 100 µM (+)-morphine, but only the PI3K inhibitor exhibits significant 
decreases in expression.  
DISCUSSION 
Analysis of the time course following (+) morphine administration in endothelial cells 
suggests that TLR4 is activated by (+)-morphine, and TLR2 may be activated as well.  While 
TLR2 transcripts significantly increased at 2 h, TLR4 transcripts did not increase significantly 
until 24 h.  Interpreting the increase in TLR2 transcripts as receptor activation is consistent with 
in vivo studies that found increased TLR2 transcripts in the brain and CNS microvasculature 
upon LPS injection (Laflamme et al., 2008).  Moreover, the upregulation of TLR2 mRNA was 
transient, occurring as quickly as 30 min after LPS exposure and diminishing at 3-6 hours—a 
trend that is mirrored in this study, where TLR2 transcripts increased at 2 h and decreased 
significantly at 4 h and 24 h.  The increase in TLR4 transcripts, however, is more controversial.  
In peripheral vascular endothelial cells upregulation of TLR4 mRNA is observed upon LPS 
exposure (Zeuke et al., 2002; Faure et al., 2001), demonstrating that an increase in mRNA 
signifies receptor activation.  In rat brains, however, TLR4 transcripts are markedly 
downregulated in response to LPS challenge (Laflamme and Rivest, 2001).  Because CNS 
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endothelial cells are at the interface of the cardiovascular system and nervous system, it is 
unclear whether upregulation of TLR4 transcripts signify activation.  At the very least TLR4 
upregulation coincides with increased CD14 and MD-2 mRNA levels, perhaps indicating that 
there is TLR4 signaling is occurring at 24 hours.  
Interestingly, the IL-1β mRNA amplification does not align with TLR4, but rather with 
TLR2.  Because IL-1β is also a product of TLR2 signaling, these results suggest that the initial 
increase of IL-1β transcripts may be due to TLR2 activation as opposed to TLR4.  However, 
there is the possibility that other downstream products, such as PGE2, are synthesized in response 
to TLR4 activation.  Since CD14 and MD-2 transcripts do not increase until after 2 h, it is most 
likely that TLR2 uses existing CD14 proteins and confers an MD-2 independent signal (since 
MD-2 is not required for TLR2).  The results show that CD14 and MD-2 transcription increases 
after TLR2 activation but at the same time as TLR4 transcription increases, suggesting that these 
accessory proteins are upregulated to accommodate increased TLR4 signaling.   
The timecourse mRNA results are not completely reflected in the In-Cell Western protein 
data. The increase in NF-κB (p65 subunit) protein at 100 µM (+)-morphine does mimic an 
increase in IκB mRNA at the same dose, but the protein levels are not significant.  CD14 protein 
expression aligns perfectly with mRNA results, showing a significant increase at 24 h at the 100 
µM (+)-morphine dose.  The clear and very significant increase in CD14 protein at 100 and 10 
µM (+)-morphine at 24 h indicates that much more CD14 is needed for the cells.  These results 
are consistent with previous research that shows robust increases in CD14 upon exposure to LPS 
(Laflamme and Rivest, 2001).  Since endothelial cells produce soluble CD14 rather than 
membrane CD14, it is likely that cells must produce much more CD14 mRNA and protein to 
compensate for protein lost in the supernatant. In other words, when CD14 is not specifically 
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targeted to the membrane, it may show a more robust increase in transcription and translation 
compared to other membrane-bound proteins in the signaling pathway that are not lost to 
supernatants in vitro or the bloodstream in vivo. MD-2 protein showed no demonstrable trend, 
which could indicate that MD-2 transcripts are degraded prior to translation.  Another possibility 
is that the binding of antibody to MD-2 is affected by changes depending on the association of 
MD-2 to TLR4 versus the plasma membrane; more research is warranted to explore the role of 
MD-2 protein.  
Of the three pharmacological TLR4 inhibitors tested, the IκB-α (BAY11-7082) inhibitor 
proved most effective.  The TLR4 inhibitor (CLI-095) and PI3K inhibitor (Wortmannin) did not 
show significant downregulation of transcripts compared to the 100 µM (+)-morphine positive 
control.  In fact, the 10 µM Wortmannin + 100 µM (+)-morphine demonstrated the opposite 
effect.  Since the literature shows that PI3K can confer both proinflammatory and anti-
inflammatory effects, it is possible that the low doses of Wortmannin (1 µM and 0.1 µM) block 
proinflammatory effects while high doses (10 µM) promote inflammatory effects. Because the 
IκB-α inhibitor is further downstream and prevents nuclear localization of NF-κB, it perhaps has 
a more direct effect than the TLR4 or PI3K inhibitors.  There may be compensatory mechanisms 
further upstream that prevent TLR4 or PI3K inhibitors from effectively downregulating TLR4, 
MD-2, CD14, and IL-1β transcripts.  For example, while the TLR4 signaling inhibitor CLI-095 
does block TLR4, it does so in a MyD88-independent manner.  Previous studies have showed 
that CLI-095 potently inhibits NF-κB activation induced by LPS in cells transiently expressing 
TLR4, MD-2, and CD14; however, it does not affect NF-κB activation that is mediated by 
MyD88 (Kawamoto et al., 2008).  Thus the lack of trends in the TLR4-signalling inhibitor data 
supports the idea that (+)-morphine induced TLR4 signaling is MyD88-dependent.  To better 
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assess the downstream effects of blocking TLR4, other TLR4 inhibitors including naltrexone and 
LPS-RS will be investigated in the future. 
 The IκB-α inhibitor demonstrated significant downregulation of all mRNA (except IL-
1β) at 10 µM drug + 100 µM (+)-morphine and at 1 µM drug + 100 µM (+)-morphine for TLR4 
and IκB.  The fact that IL-1β mRNA data does not demonstrate the same trends as the other 
proteins is actually consistent with the time course data (Experiment I).  Recall that IL-1β was 
significantly upregulated at 2 h at 100 µM (+)-morphine compared to vehicle, but that IL-1β 
levels diminished greatly at 4 h and 24 h.  Thus it is no surprise that IL-1β does not exhibit the 
same trends in response to an IκB-α inhibitor at 24 h.  This data further suggests that there may 
be another product downstream of NF-κB that is produced at 24 h.  One such product could be 
PGE2, which was downregulated (albeit not significantly) with respect to 100 µM (+)-morphine 
in a dose-dependent manner with the IκB-α inhibitor.  While the TLR4 inhibitor also did not 
demonstrate significant downregulation compared to 100 µM (+)-morphine, there was decreased 
mRNA comparatively.  The PI3K inhibitor, in fact, had the most significant effect on PGE2, with 
significant (P < 0.01) decreases at all drug+100 µM (+)-morphine doses.  These data are 
consistent with the fact that PGE2 can be produced independent of NF-κB, but is dependent on 
PI3K.   
While this study characterized the effects of different doses of (+)-morphine at different 
times on TLR4, as well as the effects of three specific TLR4 inhibitors, more research is 
certainly needed. Specifically, it would be beneficial to explore other possible downstream 
products of TLR4 signaling.  This research suggests that TLR4 may be promoting expression of 
another cytokine or protein other than IL-1β.  In addition, experimenting with a MyD88-inhibitor 
or other TLR4 signaling inhibitors that are MyD88-dependent would be useful in determining 
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whether TLR4 signaling can be more effectively blocked upstream.  It would be also be 
beneficial to investigate TLR2 further to determine whether this receptor may be responsible for 
the deleterious effects of morphine use.   In the end, examining how morphine activates TLRs 
and modulates pro-inflammatory cytokine release at the cellular level contributes to a greater 
understanding of how morphine treatment affects the body.   
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FIGURES 
 
Figure 1. Signaling pathway of Toll-like Receptor 4 (TLR4) 
TLR4 signaling requires recruitment of myeloid differentiation factor 2 (MD-2) and soluble 
CD14.  The resulting complex confers an intracellular signal via the Toll/IL-1 receptor (TIR) 
domain that either follows a MyD88-dependent or MyD88-independent pathway. In the MyD88-
dependent pathway, the signal is transduced to IL-1 receptor-associated kinases (IRAKs) that 
facilitate subsequent phosphorylations.  These phosphorylations cause IκB-α, a cytoplasmic 
protein that binds the nuclear localization sequence of NF-κB (p65 subunit), to dissociate from 
NF-κB. Binding of TLR4 also activates the PI3K/Akt/NF-κB pathway.  NF-κB translocates to 
the nucleus to promote transcription of pro-inflammatory cytokines such as IL-1β and IL-6. 
TLR2 activity requires CD14 and contributes to NF-κB activation.  TLR4 signaling also involves 
MAP kinase activity, which promotes COX2 transcription and ultimately the production of 
PGE2. (Gangloff et al., 2003; Shimazu et al., 1999; Zhang, 2011) 
 
Figure 2: The effect of 100 µM, 10 µM, 1 µM, and 0 µM doses of (+)-morphine at 2, 4, and 24 
h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=6.  
A. IL-1β mRNA was significantly upregulated in a dose dependent manner at 2 h (F3,17= 6.423, P 
< 0.05) and then decreased significantly (P < 0.05) over time.   
B. IκB mRNA was significantly upregulated in a dose-dependent manner at 2 h (F3,20= 120.17, P 
< 0.001) and 24 h (F3,20= 120.17, P < 0.0001). 
*P < 0.05, ***P < 0.001, ****P < 0.0001 with respect to vehicle 
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Figure 3: The effect of 100 µM, 10 µM, 1 µM, and 0 µM doses of (+)-morphine at 2, 4, and 24 
h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=6.  
A. TLR4 mRNA was not significantly different with respect to vehicle at 2 h or 4 h, but was 
significantly upregulated at 24 h (F3,20= 5.501, P < 0.05).  
B. TLR2 mRNA was significantly upregulated at 2 h (P < 0.05) and significantly downregulated 
at 4 h (F3,20= 21.59, P < 0.0001). 
*P < 0.05, ****P < 0.0001 with respect to vehicle 
 
Figure 4: The effect of 100 µM, 10 µM, 1 µM, and 0 µM doses of (+)-morphine at 2, 4, and 24 
h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=6.  
A. CD14 mRNA was not significantly different with respect to vehicle at 2 h or 4 h, but was 
significantly upregulated at 100 µM (+)-morphine at 24 h (F3,20= 5.924, P < 0.05).  
B. MD-2 mRNA was significantly upregulated at 100 µM (+)-morphine at 4 h (F3,20= 7.831, P < 
0.001) and approached significance at 24 h (F3,20= 7.831, P = 0.0796). 
*P < 0.05, ***P < 0.001 with respect to vehicle 
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Figure 5: The effect of 100 µM, 10 µM, 1 µM, and 0 µM doses of (+)-morphine at 2, 4, and 24 
h on protein expression 
Protein expression was measured using an In-Cell Western assay.  All (+)-morphine groups had 
n=6 and vehicle had n=4. 
A. NF-κB (p65 subunit) was not significant, though the increase at 24 h reflects similar increases 
in mRNA.  
B. CD14 protein was significantly less (F3,18= 190.10, P < 0.0001) at the 100 µM (+)-morphine 
dose compared to vehicle at 4 h, whereas both the 100 µM and 10 µM protein levels were 
significantly higher (F3,18= 11.05, P < 0.01 and P < 0.001, respectively) than vehicle at 24 h. 
C. MD-2 protein was significantly less at 100 µM and 10 µM (+)-morphine doses (F3,18= 4.294, 
P < 0.05 and P < 0.05 respectively). 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 with respect to vehicle 
 
Figure 6: The effect of 100 µM, 10 µM, 1 µM, and 0 µM doses (+)-morphine at 24 h on PGE2  
PGE2 was measured using a competitive immunoassay.  All groups had n=6.  
While there was no significant difference in protein expression at 10 µM and 1 µM doses of (+)-
morphine, PGE2 expression was significantly higher than vehicle at 100 µM (+)-morphine (F3,38= 
4.797, P < .05).  
*P < 0.05 with respect to vehicle 
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Figure 7: The effect of 10 µM, 1 µM, 0.1 µM doses of TLR4 inhibitor (CLI-095) with 100 µM 
(+)-morphine at 24 h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=4.  
A. IL-1β mRNA was greater at 10 µM CLI-095 + 100 µM (+)-morphine compared to 100 µM 
(+)-morphine, but not significantly.  All other transcript levels were close to vehicle.  
B. IκB mRNA was greater at 10 µM CLI-095 + 100 µM (+)-morphine compared to 100 µM (+)-
morphine, but not significantly.  All other transcript levels were close to vehicle. 
C. TLR4 mRNA was greater at 10 µM CLI-095 + 100 µM (+)-morphine compared to 100 µM 
(+)-morphine, but not significantly.  All other transcript levels were close to vehicle.  
D. CD14 mRNA showed no demonstrable trend or significant variation between doses. 
E. MD-2 mRNA was slightly greater at 10 µM CLI-095 + 100 µM (+)-morphine and 1 µM CLI-
095 + 100 µM (+)-morphine compared to 100 µM (+)-morphine, but not significantly.  All other 
transcript levels were close to vehicle.  
 
Figure 8: The effect of 10 µM, 1 µM, 0.1 µM doses of PI3K inhibitor (Wortmannin) with 100 
µM (+)-morphine at 24 h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=4.  
A. IL-1β mRNA was comparable across all doses and there were no significant variations with 
respect to 100 µM (+)-morphine. 
B. IκB mRNA was upregulated at 10 µM CLI-095 + 100 µM (+)-morphine, however, there were 
no significant variations with respect to 100 µM (+)-morphine. 
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C. TLR4 mRNA showed no dose-dependent trend and transcript levels for all doses of 
Wortmannin + 100 µM (+)-morphine were comparable to 100 µM (+)-morphine. 
D. CD14 mRNA was significantly less at 10 µM CLI-095 + 100 µM (+)-morphine (F3,14= 11.48, 
P < 0.001), 1 µM CLI-095 + 100 µM (+)-morphine (F3,14= 11.48, P <  0.01), and 0.1 µM CLI-
095 + 100 µM (+)-morphine (F3,14= 11.48, P <  0.01) compared to 100 µM (+)-morphine.  
Vehicle and 10 µM CLI-095 mRNA were also significantly less with respect to 100 µM (+)-
morphine (F3,14= 11.48, P < 0.01 and P < 0.0001, respectively). 
E. MD-2 mRNA showed no dose-dependent trend and transcript levels for all doses of 
Wortmannin+ 100 µM (+)-morphine was comparable to 100 µM (+)-morphine. 
**P < 0.01, ***P <  0.001, ****P <  0.0001 with respect to 100 µM (+)-morphine 
 
Figure 9: The effect of 10 µM, 1 µM, 0.1 µM doses of IκB-α inhibitor (Bay11-7082) with 100 
µM (+)-morphine at 24 h on mRNA expression 
mRNA was measured by extracting RNA, synthesizing cDNA, and comparing RT-PCR 
threshold data to GAPDH housekeeping gene.  All groups had n=4.  
A. IL-1β mRNA for all doses did not vary significantly with respect to 100 µM (+)-morphine, 
though an increase of transcripts was observed at 1 µM Bay11-7082+100 µM (+)-morphine.  
B. IκB mRNA was significantly less compared to 100 µM (+)-morphine at 1 µM drug + 100 µM 
(+)-morphine (F5,13= 17.32, P < 0.05) and 10 µM drug + 100 µM (+)-morphine (F5,13= 17.32, P <  
0.001). Vehicle and 10 µM Bay11-7082 mRNA were also significantly less (F5,13= 17.32, P < 
0.001 and P < 0.001 respectively). 
C. TLR4 mRNA were significantly downregulated at 1 µM drug + 100 µM (+)-morphine (F5,15= 
120.17, P <  0.05) and 10 µM drug + 100 µM (+)-morphine (F5,15= 120.17, P <  0.001) compared 
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to 100 µM (+)-morphine. Vehicle and 10 µM Bay11-7082 mRNA were also significantly less 
(F5,15= 120.17, P <  0.01 and P <  0.001 respectively). 
D. CD14 mRNA with respect to 100 µM (+)-morphine was significantly less at 10 µM drug + 
100 µM (+)-morphine (F5,15= 29.70, P < 0.0001), 10 µM Bay11-7082 (F5,15= 29.70, P <  0.0001), 
and vehicle (F5,15= 29.70, P <  0.001).   
E. MD-2 mRNA with respect to 100 µM (+)-morphine was significantly less at 10 µM drug + 
100 µM (+)-morphine (F5,14= 8.056, P <  0.05), 10 µM Bay11-7082 (F5,14= 8.056, P <  0.05), and 
vehicle (F5,14= 8.056, P <  0.05). 
*P <  0.05, ***P <  0.001, ****P <  0.0001 with respect to 100 µM (+)-morphine 
 
Figure 10: The effect of 10 µM, 1 µM, .1 µM doses of TLR4 inhibitors with 100 µM (+)-
morphine at 24 h on PGE2 expression 
PGE2 was measured using a competitive immunoassay.  All groups had n=4.  
A. There were no significant variations with respect to 100 µM (+)-morphine, although PGE2 
levels were higher for 100 µM (+)-morphine compared to vehicle. 
B. PGE2 is significantly less at 10 µM Wortmannin + 100 µM (+)-morphine (F5,20= 7.119, P <  
0.01), 1 µM Wortmannin + 100 µM (+)-morphine (F5,20= 7.119, P <  0.01), .1 µM Wortmannin + 
100 µM (+)-morphine (F5,20= 7.119, P <  0.01), 10 µM Wortmannin (F5,20= 7.119, P <  0.05), and 
vehicle (F5,20= 7.119, P <  0.01) compared to 100 µM (+)-morphine. 
C. PGE2 levels for the IκB-α inhibitor (Bay11-7082) show a dose dependent decrease with 
vehicle significantly less than 100 µM (+)-morphine ((F5,20= 3.55, P <  0.05). 
*P < 0.05, **P <  0.01 with respect to 100 µM (+)-morphine 
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